Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.22.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
CONSOLIDATED STATEMENTS OF OPERATIONS    
Revenues, net $ 48,272 $ 122,621
Operating expenses:    
Cost of implants and other costs 5,881 95,948
Research and development 1,605,907 4,273,815
Selling, general and administrative 3,740,783 3,167,577
Impairment of intellectual property 141,480 0
Depreciation and amortization 64,328 77,254
Total operating expenses 5,558,379 7,614,594
Loss from operations (5,510,107) (7,491,973)
Other income (expenses):    
Interest expense, net (565,684) (510,959)
Grant income 835,924 4,464,626
Other miscellaneous income 29,229 31,799
Total other income (expenses), net 299,469 3,985,466
Net loss before provision for income taxes (5,210,638) (3,506,507)
Income taxes 0 0
Net loss (5,210,638) (3,506,507)
Non-controlling interest 2,384 34,276
Dividend attributable to down round feature of warrants (70,127) 0
Net loss attributable to BioCorRx Inc. $ (5,278,381) $ (3,472,231)
Net loss per common share, basic and diluted $ (0.81) $ (0.65)
Weighted average number of common shares outstanding, basic and diluted 6,491,067 5,377,670